N-(4-fluoro-3-(6-(pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide

ID: ALA4541614

Chembl Id: CHEMBL4541614

Cas Number: 1799329-72-8

PubChem CID: 91810392

Max Phase: Preclinical

Molecular Formula: C22H16FN7O2

Molecular Weight: 429.42

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1nc(C)c(C(=O)Nc2ccc(F)c(-c3nc4ncc(-c5ccccn5)cn4n3)c2)o1

Standard InChI:  InChI=1S/C22H16FN7O2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11H,1-2H3,(H,27,31)

Standard InChI Key:  WXZFCGRYVWYYTG-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4541614

   N-(4-fluoro-3-(6-pyridin-2-yl-(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)phenyl)-2,4-dimethyl-1,3-oxazole-5-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 429.42

Molecular Weight (Monoisotopic): 429.1350

AlogP: 3.85

#Rotatable Bonds: 4

Polar Surface Area: 111.10

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.39

CX Basic pKa: 3.76

CX LogP: 3.05

CX LogD: 3.05

Aromatic Rings: 5

Heavy Atoms: 32

QED Weighted: 0.46

Np Likeness Score: -2.13

References

1. Nagendar P, Gillespie JR, Herbst ZM, Ranade RM, Molasky NMR, Faghih O, Turner RM, Gelb MH, Buckner FS..  (2019)  Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.,  10  (1): [PMID:30655955] [10.1021/acsmedchemlett.8b00498]

2. Oukoloff K, Lucero B, Francisco KR, Brunden KR, Ballatore C..  (2019)  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.,  165  [PMID:30703745] [10.1016/j.ejmech.2019.01.027]

3. Nagle A,Biggart A,Be C,Srinivas H,Hein A,Caridha D,Sciotti RJ,Pybus B,Kreishman-Deitrick M,Bursulaya B,Lai YH,Gao MY,Liang F,Mathison CJN,Liu X,Yeh V,Smith J,Lerario I,Xie Y,Chianelli D,Gibney M,Berman A,Chen YL,Jiricek J,Davis LC,Liu X,Ballard J,Khare S,Eggimann FK,Luneau A,Groessl T,Shapiro M,Richmond W,Johnson K,Rudewicz PJ,Rao SPS,Thompson C,Tuntland T,Spraggon G,Glynne RJ,Supek F,Wiesmann C,Molteni V.  (2020)  Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,  63  (19.0): [PMID:32667203] [10.1021/acs.jmedchem.0c00499]

4. Aggarwal R, Sumran G..  (2020)  An insight on medicinal attributes of 1,2,4-triazoles.,  205  [PMID:32771798] [10.1016/j.ejmech.2020.112652]

Source

Source(1):

• Scientific Literature